Shivali Fulchand
Shivali Fulchand has a total of 107 co-authors. Here are the top co-authors by number of shared publications:
- James Michael Kilgour
Stanford University
8 shared publications - Jean Yuh Tang
Department of Dermatology, Stanford University School of Medicine , Stanford, CA
3 shared publications - Emily S. Gorell
Department of Dermatology University of Colorado Anschutz Medical Campus Aurora Colorado USA
2 shared publications - Jaron Nazaroff
Department of Dermatology, Stanford University School of Medicine , Stanford, CA
2 shared publications - Jodi Y. So
Department of Dermatology, Stanford University School of Medicine, Redwood City, USA
2 shared publications - Nicki Harris
Department of Dermatology, Stanford University School of Medicine, Redwood City, USA
2 shared publications
Latest Publications
- Open Access
- 17 October 2022
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 17 (1) , 1-13
Long-term safety and efficacy of gene-corrected autologous keratinocyte grafts for recessive dystrophic epidermolysis bullosa
Background: Recessive dystrophic epidermolysis bullosa (RDEB) is a rare, devastating blistering genodermatosis caused by mutations in the COL7A1 gene, which encodes for type VII collagen and is necessary for dermal-epidermal adhesion and integrity. Disease manifestations include severe and debilitating wounds, aggressive squamous cell carcinomas, and premature death; however, there are currently no approved therapies. This Phase 1/2a, open-label study evaluated the long-term efficacy and safety of gene-corrected autologous keratinocyte grafts (EB-101) for chronic RDEB wounds. Methods: Autologous keratinocytes were harvested from participants with severe RDEB, transduced with a retrovirus containing the full-length COL7A1 gene, and grown into 5 × 7 cm (35 cm2) sheets. Gene-corrected keratinocyte sheets were then transplanted onto chronic RDEB wounds present for ≥ 12 weeks. Results: Seven adult participants with severe RDEB were grafted with six sheets each (42 total sheets) onto wounds and followed for a mean of 5.9 years (range 4–8 years). Long-term improvements in wound healing and symptoms were observed. At year five, 70% (21/30) of treated sites demonstrated ≥ 50% wound healing compared to baseline by investigator global assessment. No sites with ≥ 50% wound healing were painful or pruritic, compared to 67% (6/9) of sites with < 50% wound healing (p < 0.001) at year five. Grafts were well-tolerated throughout long-term follow-up. No serious adverse events related to treatment were reported over a mean of 5.9 years of follow-up. No persistent systemic autoimmunity against type VII collagen or replication-competent retrovirus infections were identified, and no participants developed squamous cell carcinomas related to treatment during long-term follow-up. Conclusions: Treatment with EB-101 appears safe and efficacious, and produces long-term improvements in wound healing, pain, and itch for RDEB patients. Results from the Phase 3 randomized controlled trial are forthcoming. Trial registration: ClinicalTrials.gov, NCT01263379. Registered December 15, 2010. https://clinicaltrials.gov/ct2/show/NCT01263379
- 17 October 2022
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 17 (1) , 1-13
Open AccessLong-term safety and efficacy of gene-corrected autologous keratinocyte grafts for recessive dystrophic epidermolysis bullosa
Background: Recessive dystrophic epidermolysis bullosa (RDEB) is a rare, devastating blistering genodermatosis caused by mutations in the COL7A1 gene, which encodes for type VII collagen and is necessary for dermal-epidermal adhesion and integrity. Disease manifestations include severe and debilitating wounds, aggressive squamous cell carcinomas, and premature death; however, there are currently no approved therapies. This Phase 1/2a, open-label study evaluated the long-term efficacy and safety of gene-corrected autologous keratinocyte grafts (EB-101) for chronic RDEB wounds. Methods: Autologous keratinocytes were harvested from participants with severe RDEB, transduced with a retrovirus containing the full-length COL7A1 gene, and grown into 5 × 7 cm (35 cm2) sheets. Gene-corrected keratinocyte sheets were then transplanted onto chronic RDEB wounds present for ≥ 12 weeks. Results: Seven adult participants with severe RDEB were grafted with six sheets each (42 total sheets) onto wounds and followed for a mean of 5.9 years (range 4–8 years). Long-term improvements in wound healing and symptoms were observed. At year five, 70% (21/30) of treated sites demonstrated ≥ 50% wound healing compared to baseline by investigator global assessment. No sites with ≥ 50% wound healing were painful or pruritic, compared to 67% (6/9) of sites with < 50% wound healing (p < 0.001) at year five. Grafts were well-tolerated throughout long-term follow-up. No serious adverse events related to treatment were reported over a mean of 5.9 years of follow-up. No persistent systemic autoimmunity against type VII collagen or replication-competent retrovirus infections were identified, and no participants developed squamous cell carcinomas related to treatment during long-term follow-up. Conclusions: Treatment with EB-101 appears safe and efficacious, and produces long-term improvements in wound healing, pain, and itch for RDEB patients. Results from the Phase 3 randomized controlled trial are forthcoming. Trial registration: ClinicalTrials.gov, NCT01263379. Registered December 15, 2010. https://clinicaltrials.gov/ct2/show/NCT01263379
- 13 September 2021
- Published by Wiley in Pediatric Dermatology
- Vol. 38 (5) , 1198-1201
Patient‐reported outcomes and quality of life in dominant dystrophic epidermolysis bullosa: A global cross‐sectional survey
Introduction: Dystrophic epidermolysis bullosa is a debilitating skin condition, without curative treatment. Previous research has focused on the recessive variant, which is known to cause severe disease. Limited work focusing on the clinical manifestations and outcomes of dominant dystrophic epidermolysis bullosa is found (DDEB).Methods: Analysis of an online survey of 42 DDEB patients.Results: Self‐reported severity of disease did not correlate with size of the wound or number of dressing changes, but did correlate with severity of pain reported in the last 12 months (3.4 mild vs 6.8 severe disease, P = 0.0002). Patients with severe DDEB also reported more severe internal disease symptoms, such as difficulty swallowing (62.5%, P = 0.01) and greater analgesic use during dressing changes (4.4% mild vs 81.3% severe, P = <0.001).Discussion: Patient perception of disease severity in DDEB appears to be most impacted by pain, presence of chronic open wounds, difficulty swallowing, difficulty walking, and anal strictures. As research on DDEB increases, future studies focused on these symptoms might be the most impactful for DDEB patients. However, distinguishing DDEB from other subtypes remains a challenge.
- 13 September 2021
- Published by Wiley in Pediatric Dermatology
- Vol. 38 (5) , 1198-1201
Patient‐reported outcomes and quality of life in dominant dystrophic epidermolysis bullosa: A global cross‐sectional survey
Introduction: Dystrophic epidermolysis bullosa is a debilitating skin condition, without curative treatment. Previous research has focused on the recessive variant, which is known to cause severe disease. Limited work focusing on the clinical manifestations and outcomes of dominant dystrophic epidermolysis bullosa is found (DDEB).Methods: Analysis of an online survey of 42 DDEB patients.Results: Self‐reported severity of disease did not correlate with size of the wound or number of dressing changes, but did correlate with severity of pain reported in the last 12 months (3.4 mild vs 6.8 severe disease, P = 0.0002). Patients with severe DDEB also reported more severe internal disease symptoms, such as difficulty swallowing (62.5%, P = 0.01) and greater analgesic use during dressing changes (4.4% mild vs 81.3% severe, P = <0.001).Discussion: Patient perception of disease severity in DDEB appears to be most impacted by pain, presence of chronic open wounds, difficulty swallowing, difficulty walking, and anal strictures. As research on DDEB increases, future studies focused on these symptoms might be the most impactful for DDEB patients. However, distinguishing DDEB from other subtypes remains a challenge.
- Open Access
- 1 June 2021
- Published by Cardiff University Press in The British Student Doctor Journal
- Vol. 5 (3)
Editorial
- 1 June 2021
- Published by Cardiff University Press in The British Student Doctor Journal
- Vol. 5 (3)
Open AccessEditorial
- 26 September 2019
- Published by BMJ
- Vol. 366, l5769
NHS in England to offer prenatal repair for spina bifida “within weeks,” after NICE approval
- 26 September 2019
- Published by BMJ
- Vol. 366, l5769
NHS in England to offer prenatal repair for spina bifida “within weeks,” after NICE approval
- Open Access
- 30 June 2018
- Published by Cardiff University Press in The British Student Doctor Journal
- Vol. 2 (2)
Editorial: sailing an uncharted sea
- 30 June 2018
- Published by Cardiff University Press in The British Student Doctor Journal
- Vol. 2 (2)
Open AccessEditorial: sailing an uncharted sea
- Open Access
- 31 January 2018
- Published by Cardiff University Press in The British Student Doctor Journal
- Vol. 2 (1) , 1
Editorial: mental health and medical students
- 31 January 2018
- Published by Cardiff University Press in The British Student Doctor Journal
- Vol. 2 (1) , 1
Open AccessEditorial: mental health and medical students
- Open Access
- 30 January 2018
- Published by Cardiff University Press in The British Student Doctor Journal
- Vol. 3 (1)
Editorial: Dear writer, please read the author guidelines
Welcome to the fifth issue of The British Student Doctor, and the first of 2019. This is our third year of proudly publishing this journal, with the ethos of providing a platform to medical students to develop their critical appraisal and academic publishing skills through practical experience. The breadth and quality of the articles featured in this issue are a strong testament to our success in achieving this goal, and the ability of medical students to produce high quality outcomes in research and academic discourse.
- 30 January 2018
- Published by Cardiff University Press in The British Student Doctor Journal
- Vol. 3 (1)
Open AccessEditorial: Dear writer, please read the author guidelines
Welcome to the fifth issue of The British Student Doctor, and the first of 2019. This is our third year of proudly publishing this journal, with the ethos of providing a platform to medical students to develop their critical appraisal and academic publishing skills through practical experience. The breadth and quality of the articles featured in this issue are a strong testament to our success in achieving this goal, and the ability of medical students to produce high quality outcomes in research and academic discourse.
- Open Access
- 29 June 2017
- Published by Cardiff University Press in The British Student Doctor Journal
- Vol. 1 (2) , 1
Editorial: The ethics of publishing
- 29 June 2017
- Published by Cardiff University Press in The British Student Doctor Journal
- Vol. 1 (2) , 1
Open AccessEditorial: The ethics of publishing